Cynvenio Announces ClearID Total Insight, a New Comprehensive LiquidBiopsy Monitoring Program for Breast Cancer

  • New 12-month program consists of liquid biopsy for cancer mutation detection combined with quantification of immune system performance.
  • Goal of serial blood tests is to detect signs of recurrence in survivors or metastases in patients undergoing treatment.

WESTLAKE VILLAGE – March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.

ClearID Total Insight is generally performed at regular intervals throughout the year and consists of four ClearID DNA sequencing tests, four NK-Score™ immune system assessment tests, and a BRCA 1 & 2 test provided by Cynvenio’s previously announced partner Color Genomics. The Color test identifies 30 of the most common hereditary cancer genes.

A 12-month course of ClearID Total Insight monitoring costs less than a single DNA sequencing test advertised by other genomic testing companies. It is the first test of its kind conceived to support serial genomic and immune system monitoring at a price point acceptable to doctors, payors, and patients.

The information provided by the ClearID Total Insight monitoring program can aid physicians in drug selection, risk assessment, treatment stratification, evaluation of drug resistance, and selection of monitoring frequency for their patients.

“Our new ClearID Total Insight monitoring service provides a proactive way for patients to gain greater visibility into their health status even before changes are detectable by imaging screens,” said Paul Song, MD, Chief Medical Officer of Cynvenio. “This information can provide an early warning system, complete with actionable information so patients can work with their clinicians to address an issue before it becomes too late to control or successfully treat the disease.”

Additional details are available at www.clearidmonitoring.com and www.cynvenio.com.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs are its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third-party diagnostic labs. Cynvenio is based in Westlake Village, California (Los Angeles). For more information, please visit www.cynvenio.com, www.clearidmonitoring.com and www.liquidbiopsy.com.

 

LiquidBiopsy® and ClearID®, are registered trademarks, and ClearID Breast Cancer Total Insight™ and NK-Score™ are trademarks, of Cynvenio Biosystems, Inc.